<DOC>
	<DOCNO>NCT02276612</DOCNO>
	<brief_summary>This study ass safety , efficacy tolerability elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide ( E/C/F/TAF ) HIV-infected virologically suppress adolescent 12 &lt; 18 year age .</brief_summary>
	<brief_title>Efficacy Safety Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide HIV-1 Infected Adolescents</brief_title>
	<detailed_description />
	<criteria>Key Currently stable antiretroviral regimen ≥ 6 consecutive month Weight ≥ 35 kg ( 77 lb . ) Plasma HIV1 RNA level &lt; 50 copies/mL ≥ 6 month CD4+ cell count &gt; 100 cells/μL No resistance elvitegravir ( EVG ) , emtricitabine ( FTC ) , lamivudine ( 3TC ) tenofovir ( TFV ) Hepatic transaminase ( AST ALT ) ≤ 5 x upper limit normal ( ULN ) Key A new AIDSdefining condition diagnose within 30 day prior Screening Evidence active pulmonary extrapulmonary tuberculosis disease within 3 month screen Pregnant lactate subject Hepatitis B Hepatitis C virus infection Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>